Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: NeoStem Inc

Market Cap 3.21Cr 2.79Cr 2.57Cr 2.42Cr 4.53Cr 302.1Cr 4.56Cr 31Cr 12Cr 148.88Cr 12Cr 12Cr 516.02Cr P/E 2026 *
-3.23x
P/E 2027 * -3.03x
Enterprise Value 3.21Cr 2.79Cr 2.57Cr 2.42Cr 4.53Cr 302.1Cr 4.56Cr 31Cr 12Cr 148.88Cr 12Cr 12Cr 516.02Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
79.11%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 69 05/01/2015
Director of Finance/CFO 55 01/08/2020
Chief Operating Officer 43 01/05/2016
Director TitleAgeSince
Director/Board Member 69 05/01/2015
Chairman 72 16/02/2017
Director/Board Member 66 01/11/2018
Change 5-day change 1-year change 3-year change Capi.($)
-2.23%-0.03%+61.34%+109.10% 5.62TCr
+4.60%+5.85%+54.47%+43.04% 4.38TCr
-0.95%+1.92%-12.59%-16.99% 2.33TCr
-2.79%-1.88%-4.58%+369.57% 2.13TCr
+3.22%+3.77%+19.92%-35.05% 1.58TCr
-0.67%+0.65%+14.86%-38.42% 1.56TCr
-1.33%-3.18%+27.15%+173.50% 1.32TCr
+3.07%+3.59%+25.54% - 1.2TCr
+4.95%+7.51%+123.21%+249.05% 1.19TCr
Average +0.83%+3.76%+34.37%+106.73% 2.37TCr
Weighted average by Cap. +0.50%+3.54%+38.09%+97.49%

Financials

2026 *2027 *
Net sales - -
Net income -1.83Cr -1.59Cr -1.47Cr -1.38Cr -2.59Cr -172.47Cr -2.6Cr -17Cr -6.79Cr -85Cr -6.87Cr -6.72Cr -294.6Cr -2.11Cr -1.84Cr -1.69Cr -1.59Cr -2.98Cr -198.86Cr -3Cr -20Cr -7.83Cr -98Cr -7.92Cr -7.75Cr -339.67Cr
Net Debt - -
Logo NeoStem Inc
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!